VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. META

Go back to VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update

Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus

August 15, 2016 12:20 PM EDT

Roth Capital affirms VBL Therapeutics (Nasdaq: VBLT) at Buy with a price target of $17 following Q2 results reported earlier Monday.

Analyst Joseph Pantginis commented today, In June, VBLT updated clinical results from a Phase I/II trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer. The results showed a median overall... More